BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, Schmalenberg H, Luley KB, Prasnikar N, Egger M. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncol. 2017;3:1237-1244. [PMID: 28448662 DOI: 10.1001/jamaoncol.2017.0515] [Cited by in Crossref: 133] [Cited by in F6Publishing: 126] [Article Influence: 26.6] [Reference Citation Analysis]
Number Citing Articles
1 Klempner SJ, Bhangoo MS, Luu HY, Kim ST, Chao J, Kim KM, Lee J. Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy. J Gastrointest Oncol 2018;9:1198-206. [PMID: 30603142 DOI: 10.21037/jgo.2018.09.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Klempner SJ, Maron SB, Chase L, Lomnicki S, Wainberg ZA, Catenacci DVT. Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis. Oncologist 2019;24:475-82. [PMID: 30470690 DOI: 10.1634/theoncologist.2018-0602] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
3 Brandl A, Pachmayr E, Gül-Klein S, Alberto M, Thuss-Patience P, Rau B. [Surgical treatment of peritoneal metastases of gastric cancer]. Chirurg 2018;89:669-77. [PMID: 29616280 DOI: 10.1007/s00104-018-0625-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bose K, Franck C, Müller MN, Canbay A, Link A, Venerito M. Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions. Gastroenterol Res Pract 2017;2017:5651903. [PMID: 28785280 DOI: 10.1155/2017/5651903] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
5 Breton C, Meyer A, Malka D, Matias M, De Baere T, Hammel P, Sa Cunha A, Lucchese A, Fuks D, Coriat R, Gallois C, Touchefeu Y, Maillet M, Trouilloud I, Rompteaux P, Carbonnel F, Soularue E. Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. Clin Res Hepatol Gastroenterol 2021;45:101607. [PMID: 33662776 DOI: 10.1016/j.clinre.2020.101607] [Reference Citation Analysis]
6 Procopio F, Marano S, Gentile D, Da Roit A, Basato S, Riva P, De Vita F, Torzilli G, Castoro C. Management of Liver Oligometastatic Esophageal Cancer: Overview and Critical Analysis of the Different Loco-Regional Treatments. Cancers (Basel) 2019;12:E20. [PMID: 31861604 DOI: 10.3390/cancers12010020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
7 Aboul-Enein MS, Knight W, Wulaningsih W, Foley DM, Dellaportas D, Zylstra J, Baker CR, Kelly M, Smyth E, Lagergren J, Maisey N, Allum WH, Gossage JA, Cunningham D, Davies AR; Guy's and St Thomas' Oesophago-gastric Research Group. The role of surgery after prolonged primary chemotherapy for advanced oesophageal adenocarcinoma. J Surg Oncol 2021. [PMID: 34403501 DOI: 10.1002/jso.26648] [Reference Citation Analysis]
8 Fazio N, Bertani E, Cella CA. Should cT2N0M0 be managed as a localized or locally advanced esophageal carcinoma? J Thorac Dis 2017;9:2829-34. [PMID: 29221250 DOI: 10.21037/jtd.2017.08.82] [Reference Citation Analysis]
9 Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393:1948-57. [PMID: 30982686 DOI: 10.1016/S0140-6736(18)32557-1] [Cited by in Crossref: 458] [Cited by in F6Publishing: 236] [Article Influence: 152.7] [Reference Citation Analysis]
10 Takeda FR, Garcia RN, Ueda SKN, Peixoto RD, Sallum RAA, Cecconello I. Primary tumor resection of metastatic gastric cancer in a multimodal era: Two case reports. Int J Surg Case Rep 2020;75:42-5. [PMID: 32919327 DOI: 10.1016/j.ijscr.2020.08.033] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Takahashi R, Nunobe S, Osumi H, Takahari D, Yamamoto N, Ida S, Kumagai K, Ohashi M, Sano T, Hiki N. Clinical outcomes of radical gastrectomy following trastuzumab-based chemotherapy for stage IV HER2-positive gastric or gastroesophageal junction cancer. Surg Today 2020;50:1240-8. [PMID: 32451714 DOI: 10.1007/s00595-020-02011-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Omari J, Drewes R, Orthmer M, Hass P, Pech M, Powerski M. Treatment of metastatic gastric adenocarcinoma with image-guided high-dose rate, interstitial brachytherapy as second-line or salvage therapy. Diagn Interv Radiol 2019;25:360-7. [PMID: 31348004 DOI: 10.5152/dir.2019.18390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
13 Zhou C, Ma T, Shi M, Xi W, Wu J, Yang C, Zhu Z, Zhang J. Dose-finding study of modified FLOT (mFLOT) regimen as first-line treatment in Chinese patients with metastatic adenocarcinoma of stomach. Cancer Chemother Pharmacol 2020;85:113-9. [PMID: 31691079 DOI: 10.1007/s00280-019-03982-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Pernot S, Dubreuil O, Aparicio T, Le Malicot K, Tougeron D, Lepère C, Lecaille C, Marthey L, Palle J, Bachet JB, Zaanan A, Taieb J. Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study. Br J Cancer 2018;119:424-8. [PMID: 29872148 DOI: 10.1038/s41416-018-0133-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
15 Fujitani K, Kurokawa Y, Takeno A, Kawabata R, Omori T, Imamura H, Hirao M, Endo S, Kawada J, Moon JH, Kobayashi N, Takahashi T, Yamasaki M, Takiguchi S, Mori M, Eguchi H, Doki Y; Osaka University Clinical Research Group for Gastroenterological Surgery. Prospective Multicenter Interventional Study of Surgical Resection for Liver Metastasis from Gastric Cancer: R0 Resection Rate, and Operative Morbidity and Mortality. Ann Surg Oncol 2021. [PMID: 34480277 DOI: 10.1245/s10434-021-10750-3] [Reference Citation Analysis]
16 Koo DH, Ryu MH, Lee MY, Chae H, Kim EJ, Moon MS, Kang YK. Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2-Targeted Agent in the Real-World Setting. Cancer Res Treat 2021;53:436-44. [PMID: 33070558 DOI: 10.4143/crt.2020.725] [Reference Citation Analysis]
17 Bonelli P, Borrelli A, Tuccillo FM, Silvestro L, Palaia R, Buonaguro FM. Precision medicine in gastric cancer. World J Gastrointest Oncol 2019; 11(10): 804-829 [PMID: 31662821 DOI: 10.4251/wjgo.v11.i10.804] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 34] [Article Influence: 9.7] [Reference Citation Analysis]
18 Tong Y, Zhu Y, Zhao Y, Jiang C, Wang W, Shan Z, Sun F, Liu D, Zhang J. CA724 Predicts Tumor Regression Grade in Locally Advanced Gastric Cancer Patients with Neoadjuvant Chemotherapy. J Cancer 2021;12:6465-72. [PMID: 34659537 DOI: 10.7150/jca.60694] [Reference Citation Analysis]
19 Molina JC, Al-Hinai A, Gosseling-Tardif A, Bouchard P, Spicer J, Mulder D, Mueller CL, Ferri LE. Multivisceral Resection for Locally Advanced Gastric and Gastroesophageal Junction Cancers-11-Year Experience at a High-Volume North American Center. J Gastrointest Surg. 2019;23:43-50. [PMID: 29663302 DOI: 10.1007/s11605-018-3746-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Vihervaara H, Ålgars A, Kemppainen J, Sundström J, Ristamäki R, Salminen P. Perioperative EOX treatment in operable locally advanced gastroesophageal adenocarcinoma: Prediction of tumor response by FDG –PET and histopathology. Surgical Oncology 2019;28:42-9. [DOI: 10.1016/j.suronc.2018.11.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
21 Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, Kaji M, Fukushima N, Hato S, Choda Y, Yabusaki H, Yoshida K, Ito S, Takeno A, Yasuda T, Kawachi Y, Katayama H, Fukuda H, Boku N, Sano T, Sasako M. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. The Lancet Gastroenterology & Hepatology 2019;4:208-16. [DOI: 10.1016/s2468-1253(18)30383-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
22 Leiting JL, Grotz TE. Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis. World J Gastrointest Oncol 2018; 10(10): 282-289 [PMID: 30364780 DOI: 10.4251/wjgo.v10.i10.282] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
23 Arai H, Sunakawa Y, Nakajima TE. Co-operative groups in the development of chemotherapy for gastric cancer. Jpn J Clin Oncol 2019;49:210-27. [PMID: 30508188 DOI: 10.1093/jjco/hyy176] [Reference Citation Analysis]
24 Alyami M, Bonnot PE, Mercier F, Laplace N, Villeneuve L, Passot G, Bakrin N, Kepenekian V, Glehen O. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur J Surg Oncol 2021;47:123-7. [PMID: 32561204 DOI: 10.1016/j.ejso.2020.05.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Kinoshita J, Yamaguchi T, Moriyama H, Fushida S. Current status of conversion surgery for stage IV gastric cancer. Surg Today 2021. [PMID: 33486610 DOI: 10.1007/s00595-020-02222-0] [Reference Citation Analysis]
26 Kamarajah SK, Markar SR, Phillips AW, Salti GI, Dahdaleh F, Griffiths EA. Palliative gastrectomy for metastatic gastric adenocarcinoma: A national population-based cohort study. Surgery 2021:S0039-6060(21)00699-1. [PMID: 34389165 DOI: 10.1016/j.surg.2021.07.016] [Reference Citation Analysis]
27 Polom K, Böger C, Smyth E, Marrelli D, Behrens HM, Marano L, Becker T, Lordick F, Röcken C, Roviello F. Synchronous metastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency. Eur J Surg Oncol 2018;44:626-31. [PMID: 29545085 DOI: 10.1016/j.ejso.2018.02.208] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
28 Veenstra MMK, Smithers BM, Visser E, Edholm D, Brosda S, Thomas JM, Gotley DC, Thomson IG, Wijnhoven BPL, Barbour AP. Complications and survival after hybrid and fully minimally invasive oesophagectomy. BJS Open 2021;5:zraa033. [PMID: 33609389 DOI: 10.1093/bjsopen/zraa033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Marte G, Tufo A, Steccanella F, Marra E, Federico P, Petrillo A, Maida P. Efficacy of Surgery for the Treatment of Gastric Cancer Liver Metastases: A Systematic Review of the Literature and Meta-Analysis of Prognostic Factors. J Clin Med 2021;10:1141. [PMID: 33803135 DOI: 10.3390/jcm10051141] [Reference Citation Analysis]
30 Fonseca GM, Braghiroli MIFM, Pirola Kruger JA, Coelho FF, Herman P. Is There a Role for Locoregional Therapies for Non-colorectal Gastrointestinal Malignancies? Surg Oncol Clin N Am 2021;30:125-42. [PMID: 33220801 DOI: 10.1016/j.soc.2020.08.004] [Reference Citation Analysis]
31 Alyami M, Hübner M, Grass F, Bakrin N, Villeneuve L, Laplace N, Passot G, Glehen O, Kepenekian V. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol 2019;20:e368-77. [PMID: 31267971 DOI: 10.1016/S1470-2045(19)30318-3] [Cited by in Crossref: 91] [Cited by in F6Publishing: 39] [Article Influence: 45.5] [Reference Citation Analysis]
32 Stahl KA, Olecki EJ, Dixon ME, Peng JS, Torres MB, Gusani NJ, Shen C. Gastric Cancer Treatments and Survival Trends in the United States. Curr Oncol 2020;28:138-51. [PMID: 33704182 DOI: 10.3390/curroncol28010017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Zaanan A, Bouché O, Benhaim L, Buecher B, Chapelle N, Dubreuil O, Fares N, Granger V, Lefort C, Gagniere J, Meilleroux J, Baumann AS, Vendrely V, Ducreux M, Michel P; Thésaurus National de Cancérologie Digestive (TNCD). Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis 2018;50:768-79. [PMID: 29886081 DOI: 10.1016/j.dld.2018.04.025] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
34 Uson Junior PLS, Santos VM, Bugano DDG, Victor EDS, Rother ET, Maluf FC. Systematic review and meta-analysis of docetaxel perioperative chemotherapy regimens in gastric and esophagogastric tumors. Sci Rep 2019;9:15806. [PMID: 31676841 DOI: 10.1038/s41598-019-52334-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Wang XZ, Zeng ZY, Ye X, Sun J, Zhang ZM, Kang WM. Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines. World J Gastrointest Oncol 2020; 12(1): 37-53 [PMID: 31966912 DOI: 10.4251/wjgo.v12.i1.37] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
36 Uggeri F, Ripamonti L, Pinotti E, Scotti MA, Famularo S, Garancini M, Gianotti L, Braga M, Romano F. Is there a role for treatment-oriented surgery in liver metastases from gastric cancer? World J Clin Oncol 2020; 11(7): 477-494 [PMID: 32821653 DOI: 10.5306/wjco.v11.i7.477] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Hosoda K, Azuma M, Katada C, Ishido K, Niihara M, Ushiku H, Sakuraya M, Washio M, Wada T, Watanabe A, Harada H, Tanabe S, Koizumi W, Yamashita K, Hiki N. A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction. Int J Clin Oncol 2020;25:1090-7. [PMID: 32124094 DOI: 10.1007/s10147-020-01638-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Kassar S, Samaha R, Aoun R, Khoury M, Kattan J. The concept of oligometastatic disease in gastric cancer: reality or fiction? Future Oncol 2022;18:135-8. [PMID: 34889659 DOI: 10.2217/fon-2021-1315] [Reference Citation Analysis]
39 Borggreve AS, Goense L, Brenkman HJF, Mook S, Meijer GJ, Wessels FJ, Verheij M, Jansen EPM, van Hillegersberg R, van Rossum PSN, Ruurda JP. Imaging strategies in the management of gastric cancer: current role and future potential of MRI. Br J Radiol 2019;92:20181044. [PMID: 30789792 DOI: 10.1259/bjr.20181044] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
40 Tang K, Zhang B, Dong L, Wang L, Tang Z. Radiofrequency ablation versus traditional liver resection and chemotherapy for liver metastases from gastric cancer. J Int Med Res 2020;48:300060520940509. [PMID: 32687001 DOI: 10.1177/0300060520940509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
41 Granieri S, Altomare M, Bruno F, Paleino S, Bonomi A, Germini A, Facciorusso A, Fagnani D, Bovo G, Cotsoglou C. Surgical treatment of gastric cancer liver metastases: Systematic review and meta-analysis of long-term outcomes and prognostic factors. Crit Rev Oncol Hematol 2021;163:103313. [PMID: 34044098 DOI: 10.1016/j.critrevonc.2021.103313] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Parisi A, Porzio G, Ficorella C. Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future. Cancers (Basel) 2020;12:E2598. [PMID: 32932914 DOI: 10.3390/cancers12092598] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Inoue H, Kosuga T, Kubota T, Konishi H, Shiozaki A, Okamoto K, Fujiwara H, Otsuji E. Significance of a preoperative systemic immune-inflammation index as a predictor of postoperative survival outcomes in gastric cancer. World J Surg Oncol 2021;19:173. [PMID: 34118953 DOI: 10.1186/s12957-021-02286-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Huang J, Yao H, Li Y, Dong M, Han C, He L, Huang X, Xia T, Yi Z, Wang H, Zhang Y, He J, Liang C, Liu Z. Development and validation of a CT-based radiomics nomogram for preoperative prediction of tumor histologic grade in gastric adenocarcinoma. Chin J Cancer Res 2021;33:69-78. [PMID: 33707930 DOI: 10.21147/j.issn.1000-9604.2021.01.08] [Reference Citation Analysis]
45 Xu M, Hu K, Liu Y, Huang Y, Liu S, Chen Y, Wang D, Zhou S, Zhang Q, Mei N, Lu H, Li F, Gao X, Chen J. Systemic metastasis-targeted nanotherapeutic reinforces tumor surgical resection and chemotherapy. Nat Commun 2021;12:3187. [PMID: 34045459 DOI: 10.1038/s41467-021-23466-5] [Reference Citation Analysis]
46 Katsaounis P, Kotsakis A, Kentepozidis N, Polyzos A, Bakogeorgos M, Koinis F, Vamvakas L, Vardakis N, Kalbakis K, Boukovinas I, Varthalitis II, Prinarakis E, Georgoulias V, Souglakos J. Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group. Ann Gastroenterol 2018;31:65-70. [PMID: 29333068 DOI: 10.20524/aog.2017.0215] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
47 Aigner K, Vashist YK, Selak E, Gailhofer S, Aigner KR. Efficacy of Regional Chemotherapy Approach in Peritoneal Metastatic Gastric Cancer. J Clin Med 2021;10:5322. [PMID: 34830604 DOI: 10.3390/jcm10225322] [Reference Citation Analysis]
48 Sun KY, Hu HT, Chen SL, Ye JN, Li GH, Chen LD, Peng JJ, Feng ST, Yuan YJ, Hou X, Wu H, Li X, Wu TF, Wang W, Xu JB. CT-based radiomics scores predict response to neoadjuvant chemotherapy and survival in patients with gastric cancer. BMC Cancer 2020;20:468. [PMID: 32450841 DOI: 10.1186/s12885-020-06970-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
49 Marano L, Marrelli D, Sammartino P, Biacchi D, Graziosi L, Marino E, Coccolini F, Fugazzola P, Valle M, Federici O, Baratti D, Deraco M, Di Giorgio A, Macrì A, Pasqual EM, Framarini M, Vaira M, Roviello F; “Italian Peritoneal Surface Malignancies Oncoteam - S.I.C.O.”. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Synchronous Peritoneal Metastases: Multicenter Study of 'Italian Peritoneal Surface Malignancies Oncoteam-S.I.C.O.'. Ann Surg Oncol 2021. [PMID: 34057569 DOI: 10.1245/s10434-021-10157-0] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
50 Runkel M, Verst R, Spiegelberg J, Fichtner-Feigl S, Hoeppner J, Glatz T. Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival. BMC Surg 2021;21:35. [PMID: 33435947 DOI: 10.1186/s12893-020-01035-9] [Reference Citation Analysis]
51 Wu L, Feng Y, Wu Z, Xu H, Zhang C, Ning J, Wang R, Chen J, Xie M, Zhang Y, Bu L, Hao J, Ma T. Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis. World J Surg Oncol 2021;19:272. [PMID: 34507562 DOI: 10.1186/s12957-021-02390-4] [Reference Citation Analysis]
52 Cortés-Guiral D, Hübner M, Alyami M, Bhatt A, Ceelen W, Glehen O, Lordick F, Ramsay R, Sgarbura O, Van Der Speeten K, Turaga KK, Chand M. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers 2021;7:91. [PMID: 34916522 DOI: 10.1038/s41572-021-00326-6] [Reference Citation Analysis]
53 Luo Z, Rong Z, Huang C. Surgery Strategies for Gastric Cancer With Liver Metastasis. Front Oncol 2019;9:1353. [PMID: 31921626 DOI: 10.3389/fonc.2019.01353] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
54 Jimenez-Fonseca P, Carmona-Bayonas A, Martínez de Castro E, Custodio A, Pericay Pijaume C, Hernandez R, Aguado G, Castro Unanua N, Cano JM, López F, Garrido M, Fernández Montes A, Visa L, Sánchez Cánovas M, Limón ML, Martínez Lago N, Pimentel P, Hurtado A, Azkárate A, Longo F, Diez M, Arias-Martinez A, Sauri T, Martín Carnicero A, Mangas M, Martín Richard M, Granja M, Ramchandani A, Hernández Pérez C, Cerdá P, Gil-Negrete A, Calvo M, Vidal Tocino R, Gallego J. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit? Gastric Cancer 2021;24:445-56. [PMID: 32970266 DOI: 10.1007/s10120-020-01116-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Levy A, Wagner AD, Chargari C, Moehler M, Verheij M, Durand-Labrunie J, Kissel M, Chirat E, Burtin P, Ducreux M, Boige V, Nilsson M, Boku N, Chau I, Deutsch E. Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position. Eur J Cancer 2020;135:103-12. [PMID: 32563014 DOI: 10.1016/j.ejca.2020.04.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Stahl M, Maderer A, Lordick F, Mihaljevic AL, Kanzler S, Hoehler T, Thuss-patience P, Mönig S, Kunzmann V, Schroll S, Sandermann A, Tannapfel A, Meyer H, Schuhmacher C, Wilke H, Moehler M. Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801). European Journal of Cancer 2018;93:119-26. [DOI: 10.1016/j.ejca.2018.01.079] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
57 Deleporte A, Van den Eynde M, Forget F, Holbrechts S, Delaunoit T, Houbiers G, Kalantari HR, Laurent S, Vanderstraeten E, De Man M, Vergauwe P, Clausse M, Van Der Auwera J, D'Hondt L, Pierre P, Ghillemijn B, Covas A, Paesmans M, Ameye L, Awada A, Sclafani F, Hendlisz A. Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study. Cancer Med 2021;10:4366-74. [PMID: 34057299 DOI: 10.1002/cam4.3976] [Reference Citation Analysis]
58 Eveno C, Jouvin I, Pocard M. PIPAC EstoK 01: Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin (PIPAC C/D) in gastric peritoneal metastasis: a randomized and multicenter phase II study. Pleura Peritoneum. 2018;3:20180116. [PMID: 30911659 DOI: 10.1515/pp-2018-0116] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
59 Borggreve AS, Kingma BF, Domrachev SA, Koshkin MA, Ruurda JP, Hillegersberg R, Takeda FR, Goense L. Surgical treatment of esophageal cancer in the era of multimodality management. Ann N Y Acad Sci 2018;1434:192-209. [DOI: 10.1111/nyas.13677] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
60 Li W, Jiang H, Yu Y, Wang Y, Wang Z, Cui Y, Shen K, Shen Z, Fang Y, Liu T. Outcomes of gastrectomy following upfront chemotherapy in advanced gastric cancer patients with a single noncurable factor: a cohort study. Cancer Manag Res 2019;11:2007-13. [PMID: 30881125 DOI: 10.2147/CMAR.S192570] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
61 Chen Y, Liu D, Xiao J, Xiang J, Liu A, Chen S, Liu J, Hu X, Peng J. Nomogram for Predicting Survival in Advanced Gastric Cancer after Neoadjuvant Chemotherapy and Radical Surgery. Gastroenterol Res Pract 2021;2021:2923700. [PMID: 34367276 DOI: 10.1155/2021/2923700] [Reference Citation Analysis]
62 Khan K, Rane JK, Cunningham D, Rao S, Watkins D, Starling N, Kalaitzaki E, Forster M, Braconi C, Valeri N, Gerlinger M, Chau I. Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. Clinical Colorectal Cancer 2019;18:64-71.e1. [DOI: 10.1016/j.clcc.2018.09.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
63 Takeda FR, Kodama Pertille Ramos MF, Pereira MA, Muniz RR, Tustumi F, Biachi de Castria T, Aissar Sallum RA, Zilberstein B, Junior UR, Cecconello I. Predictive factors of recurrence in adenocarcinoma of the esophagogastric junction in the multimodal era. Am J Surg 2021;221:631-6. [PMID: 32862976 DOI: 10.1016/j.amjsurg.2020.07.031] [Reference Citation Analysis]
64 Cowling J, Gorman B, Riaz A, Bundred JR, Kamarajah SK, Evans RPT, Singh P, Griffiths EA. Peri-operative Outcomes and Survival Following Palliative Gastrectomy for Gastric Cancer: a Systematic Review and Meta-analysis. J Gastrointest Cancer 2021;52:41-56. [PMID: 32959118 DOI: 10.1007/s12029-020-00519-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Weiss ARR, Donlon NE, Schlitt HJ, Hackl C. Resection of oesophageal and oesophagogastric junction cancer liver metastases - a summary of current evidence. Langenbecks Arch Surg 2021. [PMID: 34860291 DOI: 10.1007/s00423-021-02387-3] [Reference Citation Analysis]
66 Portuondo JI, Tran Cao HS, da Costa WL, Sada YH, Harris AHS, Massarweh NN. Treatment approach, hospital practice patterns, and receipt of multimodality therapy as measures of quality for locally advanced gastric cancer. J Surg Oncol 2021;123:1724-35. [PMID: 33721353 DOI: 10.1002/jso.26460] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
67 Fornaro L, Vivaldi C, Parnofiello A, Ugolini C, Aprile G, De Maglio G, Pecora I, Iacono D, Crivelli F, Catanese S, Cardellino GG, Lencioni M, Vasile E, Salani F, Clerico M, Calvetti L, Falcone A, Fasola G, Fontanini G, Montagnani F. Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. Br J Cancer 2019;120:522-6. [PMID: 30745584 DOI: 10.1038/s41416-019-0399-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
68 Freiin Grote A, Halske C, Behrens HM, Krüger S, Wilhelm F, Egberts JH, Röcken C. Expression of LGR5, FZD7, TROY, and MIST1 in Perioperatively Treated Gastric Carcinomas and Correlation with Therapy Response. Dis Markers 2019;2019:8154926. [PMID: 31827644 DOI: 10.1155/2019/8154926] [Reference Citation Analysis]
69 Beckert S, Königsrainer A. Oligometastasierung beim Magen- und Ösophaguskarzinom: Aktuelle Studienlage und chirurgische Konzepte. Chirurg 2018;89:505-9. [DOI: 10.1007/s00104-018-0645-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
70 Jung MK, Ott K, Chevallay M, Mönig SP. [Treatment options for oligometastatic gastric cancer]. Chirurg 2021;92:515-21. [PMID: 33544151 DOI: 10.1007/s00104-021-01353-5] [Reference Citation Analysis]
71 Jung MK, Schmidt T, Chon SH, Chevallay M, Berlth F, Akiyama J, Gutschow CA, Mönig SP. Current surgical treatment standards for esophageal and esophagogastric junction cancer.Ann N Y Acad Sci. 2020;1482:77-84. [PMID: 32798235 DOI: 10.1111/nyas.14454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Bonnot PE, Lintis A, Mercier F, Benzerdjeb N, Passot G, Pocard M, Meunier B, Bereder JM, Abboud K, Marchal F, Quenet F, Goere D, Msika S, Arvieux C, Pirro N, Wernert R, Rat P, Gagnière J, Lefevre JH, Courvoisier T, Kianmanesh R, Vaudoyer D, Rivoire M, Meeus P, Villeneuve L, Piessen G, Glehen O; FREGAT and BIG-RENAPE Networks . Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study). Br J Surg 2021;108:1225-35. [PMID: 34498666 DOI: 10.1093/bjs/znab200] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
73 Fritsch R, Hoeppner J. Oxaliplatin in perioperative chemotherapy for gastric and gastroesophageal junction (GEJ) adenocarcinoma. Expert Rev Gastroenterol Hepatol 2019;13:285-91. [PMID: 30791774 DOI: 10.1080/17474124.2019.1573143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
74 Wang K, Li E, Busuttil RA, Kong JC, Pattison S, Sung JJY, Yu J, El-Omar EM, Simpson JA, Boussioutas A. A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer. Ther Adv Med Oncol 2020;12:1758835920930359. [PMID: 32754227 DOI: 10.1177/1758835920930359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
75 Jin P, Ji X, Tian Y. Surgical management of oligometastatic disease in gastric cancer. Clin Res Hepatol Gastroenterol 2020;44:638-45. [PMID: 32147440 DOI: 10.1016/j.clinre.2020.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
76 Rawicz-Pruszyński K, Ciseł B, Mlak R, Mielko J, Skórzewska M, Kwietniewska M, Pikuła A, Gęca K, Sędłak K, Kurylcio A, Polkowski WP. The Role of the Lymph Node Ratio in Advanced Gastric Cancer After Neoadjuvant Chemotherapy. Cancers (Basel) 2019;11:E1914. [PMID: 31805755 DOI: 10.3390/cancers11121914] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
77 Shen J, Cao B, Wang Y, Xiao A, Qin J, Wu J, Yan Q, Hu Y, Yang C, Cao Z, Hu J, Yin P, Xie D, Gong J. Prospective randomized controlled trial to compare laparoscopic distal gastrectomy (D2 lymphadenectomy plus complete mesogastrium excision, D2 + CME) with conventional D2 lymphadenectomy for locally advanced gastric adenocarcinoma: study protocol for a randomized controlled trial. Trials 2018;19:432. [PMID: 30092843 DOI: 10.1186/s13063-018-2790-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
78 Ma F, Zhang Y, Peng L, Zhang Z, Yang W, Chai J, Zhang B, Ji S, Hua Y, Chen X, Luo S. Which is the optimal management for locally advanced gastric cancer patients with TRG 0 and 1 after R0 resection? Ann Transl Med 2020;8:948. [PMID: 32953748 DOI: 10.21037/atm-20-3986] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Depypere LP, Moons J, Lerut TE, Coosemans W, Van Veer H, Nafteux PR. Palliative esophagectomy in unexpected metastatic disease: sense or nonsense? Asian Cardiovasc Thorac Ann 2018;26:552-7. [PMID: 30185072 DOI: 10.1177/0218492318797228] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
80 Fornaro L, Fanotto V, Musettini G, Uccello M, Rimassa L, Vivaldi C, Fontanella C, Leone F, Giampieri R, Rosati G, Lencioni M, Santini D, Di Donato S, Tomasello G, Brunetti O, Pietrantonio F, Bergamo F, Scartozzi M, Avallone A, Lutrino SE, Melisi D, Antonuzzo L, Pellegrino A, Gerratana L, Cordio S, Vasile E, Aprile G. Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. Future Oncol 2017;13:2265-75. [PMID: 28976226 DOI: 10.2217/fon-2017-0246] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
81 Diniz TP, da Costa WL Jr, Gomes CC, de Jesus VHF, Felismino TC, Torres SM, Ribeiro HSC, Diniz AL, de Godoy AL, de Farias IC, Dias-Neto E, Curado MP, Coimbra FJF. Symptomatic Recurrence and Survival Outcomes After Curative Treatment of Gastric Cancer: Does Intensive Follow-up Evaluation Improve Survival? Ann Surg Oncol 2021. [PMID: 34782973 DOI: 10.1245/s10434-021-10724-5] [Reference Citation Analysis]
82 Alyami M, Mercier F, Siebert M, Bonnot PE, Laplace N, Villeneuve L, Passot G, Glehen O, Bakrin N, Kepenekian V. Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2021;47:128-33. [PMID: 31253545 DOI: 10.1016/j.ejso.2019.06.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
83 Li Z, Wang Y, Ying X, Shan F, Wu Z, Zhang L, Li S, Jia Y, Ren H, Ji J. Different prognostic implication of ypTNM stage and pTNM stage for gastric cancer: a propensity score-matched analysis. BMC Cancer 2019;19:80. [PMID: 30651085 DOI: 10.1186/s12885-019-5283-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Chevallay M, Bollschweiler E, Chandramohan SM, Schmidt T, Koch O, Demanzoni G, Mönig S, Allum W. Cancer of the gastroesophageal junction: a diagnosis, classification, and management review. Ann N Y Acad Sci 2018;1434:132-8. [PMID: 30138540 DOI: 10.1111/nyas.13954] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
85 Zhang F, Huang X, Song Y, Gao P, Zhou C, Guo Z, Shi J, Wu Z, Wang Z. Conversion Surgery for Stage IV Gastric Cancer. Front Oncol 2019;9:1158. [PMID: 31788445 DOI: 10.3389/fonc.2019.01158] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
86 Schurink B, Mazza E, Ruurda JP, Roeling TAP, Bleys RLAW, van Hillegersberg R. Metastatic incidence of (PET)CT positive lung hilar and retroperitoneal lymph nodes in esophageal cancer patients. Surg Oncol 2020;33:170-6. [PMID: 32561084 DOI: 10.1016/j.suronc.2020.02.012] [Reference Citation Analysis]
87 Gockel I, Lordick F. [Neoadjuvant chemotherapy for gastric cancer. Frequent overtreatment or meaningful concept?]. Chirurg 2020;91:384-90. [PMID: 32112151 DOI: 10.1007/s00104-020-01141-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, Novotny A, Pauligk C, Homann N, Jungbluth T, Reissfelder C, Caca K, Retter S, Horndasch E, Gumpp J, Bolling C, Fuchs KH, Blau W, Padberg W, Pohl M, Wunsch A, Michl P, Mannes F, Schwarzbach M, Schmalenberg H, Hohaus M, Scholz C, Benckert C, Knorrenschild JR, Kanngießer V, Zander T, Alakus H, Hofheinz RD, Roedel C, Shah MA, Sasako M, Lorenz D, Izbicki J, Bechstein WO, Lang H, Moenig SP. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer 2017;17:893. [PMID: 29282088 DOI: 10.1186/s12885-017-3918-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
89 Claassen YHM, Bastiaannet E, Hartgrink HH, Dikken JL, de Steur WO, Slingerland M, Verhoeven RHA, van Eycken E, de Schutter H, Lindblad M, Hedberg J, Johnson E, Hjortland GO, Jensen LS, Larsson HJ, Koessler T, Chevallay M, Allum WH, van de Velde CJH. International comparison of treatment strategy and survival in metastatic gastric cancer. BJS Open 2019;3:56-61. [PMID: 30734016 DOI: 10.1002/bjs5.103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
90 Jiang D, Shu C, Zhang W, Sun L, Zhang M, He Y, Owen G, Jin W, He D, Deng X, Liu X. Low level of microsatellite instability correlates with short disease-free survival of gastric cancer patients undergoing neoadjuvant chemotherapy. Virchows Arch 2021;478:231-40. [PMID: 32588133 DOI: 10.1007/s00428-020-02878-6] [Reference Citation Analysis]
91 Hirahara T, Arigami T, Yanagita S, Matsushita D, Uchikado Y, Kita Y, Mori S, Sasaki K, Omoto I, Kurahara H, Maemura K, Okubo K, Uenosono Y, Ishigami S, Natsugoe S. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer. 2019;19:672. [PMID: 31286873 DOI: 10.1186/s12885-019-5903-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
92 Saiz Martínez R, Dromain C, Vietti Violi N. Imaging of Gastric Carcinomatosis. J Clin Med 2021;10:5294. [PMID: 34830575 DOI: 10.3390/jcm10225294] [Reference Citation Analysis]
93 D'Ugo D, Agnes A, Grieco M, Biondi A, Persiani R. Global updates in the treatment of gastric cancer: a systematic review. Part 2: perioperative management, multimodal therapies, new technologies, standardization of the surgical treatment and educational aspects. Updates Surg 2020;72:355-78. [PMID: 32306277 DOI: 10.1007/s13304-020-00771-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Zhang YJ, Wang YY, Yang Q, Li JB. Scaphoid metastasis as the first sign of occult gastroesophageal junction cancer: A case report. World J Clin Cases 2020; 8(7): 1287-1294 [PMID: 32337204 DOI: 10.12998/wjcc.v8.i7.1287] [Reference Citation Analysis]
95 Yang LP, Wang ZX, He MM, Jin Y, Ren C, Wang ZQ, Wang FH, Li YH, Wang F, Xu RH. The survival benefit of palliative gastrectomy and/or metastasectomy in gastric cancer patients with synchronous metastasis: a population-based study using propensity score matching and coarsened exact matching. J Cancer 2019;10:602-10. [PMID: 30719157 DOI: 10.7150/jca.28842] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
96 Li S, Zang L. The Effectiveness of Gastrectomy With Chemoradiotherapy Among Stage IV Gastric Adenocarcinoma: A Population-Based Analysis. Front Oncol 2020;10:630. [PMID: 32411605 DOI: 10.3389/fonc.2020.00630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 Gronnier C, Collet D. New Trends in Esophageal Cancer Management. Cancers (Basel) 2021;13:3030. [PMID: 34204314 DOI: 10.3390/cancers13123030] [Reference Citation Analysis]
98 Wan T, Zhang XF, Liang C, Liao CW, Li JY, Zhou YM. The Prognostic Value of a Pathologic Complete Response After Neoadjuvant Therapy for Digestive Cancer: Systematic Review and Meta-Analysis of 21 Studies. Ann Surg Oncol. 2019;26:1412-1420. [PMID: 30805807 DOI: 10.1245/s10434-018-07147-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
99 Schlintl V, Huemer F, Greil R, Weiss L. Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. J Gastrointest Oncol 2021;12:906-9. [PMID: 34012679 DOI: 10.21037/jgo-20-230] [Reference Citation Analysis]
100 Fornaro L, Vasile E, Aprile G, Goetze TO, Vivaldi C, Falcone A, Al-Batran SE. Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions. Cancer Treat Rev 2018;69:90-100. [PMID: 29957366 DOI: 10.1016/j.ctrv.2018.06.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
101 Schoop H, Bregenzer A, Halske C, Behrens HM, Krüger S, Egberts JH, Röcken C. Therapy Resistance in Neoadjuvantly Treated Gastric Cancer and Cancer of the Gastroesophageal Junction is Associated with an Increased Expression of Immune Checkpoint Inhibitors-Comparison Against a Therapy Naïve Cohort. Transl Oncol 2020;13:165-76. [PMID: 31865179 DOI: 10.1016/j.tranon.2019.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
102 Lutz MP, Zalcberg JR, Ducreux M, Adenis A, Allum W, Aust D, Carneiro F, Grabsch HI, Laurent-Puig P, Lordick F, Möhler M, Mönig S, Obermannova R, Piessen G, Riddell A, Röcken C, Roviello F, Schneider PM, Seewald S, Smyth E, van Cutsem E, Verheij M, Wagner AD, Otto F. The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. Eur J Cancer 2019;112:1-8. [PMID: 30878666 DOI: 10.1016/j.ejca.2019.01.106] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
103 Mielko J, Rawicz-Pruszyński K, Skórzewska M, Ciseł B, Pikuła A, Kwietniewska M, Gęca K, Sędłak K, Kurylcio A, Polkowski WP. Conversion Surgery with HIPEC for Peritoneal Oligometastatic Gastric Cancer. Cancers (Basel) 2019;11:E1715. [PMID: 31684115 DOI: 10.3390/cancers11111715] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
104 Chen Q, Wang X, Ding R, Wang Z. Intelligent Algorithm-Based CT Imaging for Evaluation of Efficacy of Docetaxel Combined with Fluorouracil on Patients with Gastric Cancer. J Healthc Eng 2021;2021:1040374. [PMID: 34659676 DOI: 10.1155/2021/1040374] [Reference Citation Analysis]
105 Lo Dico R, Gornet JM, Guglielmo N, Zaanan A, Taieb J, Pocard M. Bidirectional chemotherapy combining intraperitoneal docetaxel with intravenous 5-fluorouracil and oxaliplatin for patients with unresectable peritoneal metastasis from gastric cancer: the first study in Western countries. Pleura Peritoneum 2020;5:20190035. [PMID: 32566725 DOI: 10.1515/pp-2019-0035] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Bonnot P, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, Bereder J, Abboud K, Marchal F, Quenet F, Goere D, Msika S, Arvieux C, Pirro N, Wernert R, Rat P, Gagnière J, Lefevre JH, Courvoisier T, Kianmanesh R, Vaudoyer D, Rivoire M, Meeus P, Passot G, Glehen O; on behalf of the FREGAT and BIG-RENAPE Networks. Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis. JCO 2019;37:2028-40. [DOI: 10.1200/jco.18.01688] [Cited by in Crossref: 73] [Cited by in F6Publishing: 39] [Article Influence: 24.3] [Reference Citation Analysis]
107 Brandl A, Yonemura Y, Glehen O, Sugarbaker P, Rau B. Long term survival in patients with peritoneal metastasised gastric cancer treated with cytoreductive surgery and HIPEC: A multi-institutional cohort from PSOGI. Eur J Surg Oncol 2021;47:172-80. [PMID: 33071173 DOI: 10.1016/j.ejso.2020.10.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
108 Rau B, Brandl A, Thuss-Patience P, Bergner F, Raue W, Arnold A, Horst D, Pratschke J, Biebl M. The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis. Gastric Cancer. 2019;22:1226-1237. [PMID: 31065877 DOI: 10.1007/s10120-019-00969-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
109 Rawicz-Pruszyński K, van Sandick JW, Mielko J, Ciseł B, Polkowski WP. Current challenges in gastric cancer surgery: European perspective. Surg Oncol 2018;27:650-6. [PMID: 30449488 DOI: 10.1016/j.suronc.2018.08.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
110 Petrillo A, Pompella L, Tirino G, Pappalardo A, Laterza MM, Caterino M, Orditura M, Ciardiello F, Lieto E, Galizia G, Castoro C, De Vita F. Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. Cancers (Basel) 2019;11:E399. [PMID: 30901943 DOI: 10.3390/cancers11030399] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
111 Yordanova K, Stilgenbauer S, Bohle RM, Lesan V, Thurner L, Kaddu-Mulindwa D, Bittenbring JT, Scharberger M, Aßmann G, Bewarder M. Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement. Br J Haematol 2019;186:e203-7. [PMID: 31257571 DOI: 10.1111/bjh.16082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
112 Goetze OT, Al-Batran SE, Chevallay M, Mönig SP. Multimodal treatment in locally advanced gastric cancer. Updates Surg 2018;70:173-9. [PMID: 29946806 DOI: 10.1007/s13304-018-0539-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
113 Terashima M, Yoshikawa T, Boku N, Ito S, Tsuburaya A, Iwasaki Y, Fukagawa T, Tokunaga M, Sano T, Sasako M;  Stomach Cancer Study Group;  Japan Clinical Oncology Group. Current status of perioperative chemotherapy for locally advanced gastric cancer and JCOG perspectives. Jpn J Clin Oncol. 2020;50:528-534. [PMID: 32134452 DOI: 10.1093/jjco/hyaa005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
114 Jung JO, Nienhüser H, Schleussner N, Schmidt T. Oligometastatic Gastroesophageal Adenocarcinoma: Molecular Pathophysiology and Current Therapeutic Approach. Int J Mol Sci 2020;21:E951. [PMID: 32023907 DOI: 10.3390/ijms21030951] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
115 Alshahrani S, Baabbad F, Bahobail M, Hawsawi A, Jastania E, Bamousa S, Shobair A, Zaidi SF. Survival Time in Treatment Modalities of Gastric Carcinoma at King Khalid Hospital- Jeddah Saudi Arabia: a Retrospective Cohort Study. Mater Sociomed 2020;32:271-6. [PMID: 33628129 DOI: 10.5455/msm.2020.32.271-276] [Reference Citation Analysis]
116 Hsieh YY, Tung SY, Pan HY, Yen CW, Xu HW, Deng YF, Lin YJ, Hsu WT, Wu CS, Li C. Upregulation of bone morphogenetic protein 1 is associated with poor prognosis of late-stage gastric Cancer patients. BMC Cancer 2018;18:508. [PMID: 29720137 DOI: 10.1186/s12885-018-4383-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
117 Gül-Klein S, Schmuck R, Modest DP, Pratschke J. [Treatment of colorectal and non-colorectal liver metastases: rationale for neoadjuvant therapeutic concepts]. Chirurg 2020;91:396-404. [PMID: 32291472 DOI: 10.1007/s00104-020-01133-7] [Reference Citation Analysis]
118 Diniz TP, da Costa WL Jr, Fonseca de Jesus VH, Ribeiro HSC, Diniz AL, de Godoy AL, de Farias IC, Torres SM, Felismino TC, Coimbra FJF. Does hipec improve outcomes in gastric cancer patients treated with perioperative chemotherapy and radical surgery? A propensity-score matched analysis. J Surg Oncol 2020;121:823-32. [PMID: 31950511 DOI: 10.1002/jso.25823] [Reference Citation Analysis]
119 Fornaro L, Spallanzani A, de Vita F, D'Ugo D, Falcone A, Lorenzon L, Tirino G, Cascinu S; GAIN (GAstric Cancer Italian Network). Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). Cancers (Basel) 2021;13:1304. [PMID: 33804024 DOI: 10.3390/cancers13061304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Seesing MFJ, van der Veen A, Brenkman HJF, Stockmann HBAC, Nieuwenhuijzen GAP, Rosman C, van den Wildenberg FJH, van Berge Henegouwen MI, van Duijvendijk P, Wijnhoven BPL, Stoot JHMB, Lacle M, Ruurda JP, van Hillegersberg R; Gastroesophageal Metastasectomy Group. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study. Dis Esophagus 2019;32:doz034. [PMID: 31220859 DOI: 10.1093/dote/doz034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
121 Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, Azuma M, Sakamoto T, Shitara K, Tamura T, Chin K, Hata H, Nakamori M, Hara H, Yasui H, Katayama H, Fukuda H, Yoshikawa T, Sasako M, Terashima M. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 2019;4:501-10. [PMID: 31101534 DOI: 10.1016/S2468-1253(19)30083-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 11.7] [Reference Citation Analysis]
122 Salati M, Valeri N, Spallanzani A, Braconi C, Cascinu S. Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications. Eur J Surg Oncol 2019;45:1479-82. [PMID: 30448343 DOI: 10.1016/j.ejso.2018.11.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Chen K, Deng X, Yang Z, Yu D, Zhang X, Li W, Xie D, He Z, Cheng D. Sites of distant metastases and the cancer-specific survival of metastatic Siewert type II esophagogastric junction adenocarcinoma: a population-based study. Expert Rev Gastroenterol Hepatol 2020;14:491-7. [PMID: 32324423 DOI: 10.1080/17474124.2020.1760839] [Reference Citation Analysis]
124 Montagnani F, Crivelli F, Aprile G, Vivaldi C, Pecora I, De Vivo R, Clerico MA, Fornaro L. Long-term survival after liver metastasectomy in gastric cancer: Systematic review and meta-analysis of prognostic factors. Cancer Treat Rev. 2018;69:11-20. [PMID: 29860024 DOI: 10.1016/j.ctrv.2018.05.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
125 Götze TO, Piso P, Lorenzen S, Bankstahl US, Pauligk C, Elshafei M, Amato G, Reim D, Bechstein WO, Königsrainer A, Mönig SP, Rau B, Schwarzbach M, Al-Batran SE. Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO. BMC Cancer 2021;21:1158. [PMID: 34715810 DOI: 10.1186/s12885-021-08872-8] [Reference Citation Analysis]
126 Zhang Y, Zhang B, Yang J, Zhang J, Zhang W. Perioperative Safety and Effectiveness of Neoadjuvant Therapy with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Plus Apatinib in Locally Advanced Gastric Cancer. Cancer Manag Res 2021;13:2279-86. [PMID: 33732020 DOI: 10.2147/CMAR.S304093] [Reference Citation Analysis]
127 Zhang K, Chen L. Chinese consensus on the diagnosis and treatment of gastric cancer with liver metastases. Ther Adv Med Oncol. 2020;12:1758835920904803. [PMID: 32127925 DOI: 10.1177/1758835920904803] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
128 Chen M, He FQ, Liao MS, Yang C, Chen XD. Gastrectomy with omentum preservation versus gastrectomy with omentectomy for locally advanced gastric cancer: A systematic review and meta-analysis. Int J Surg 2021;96:106176. [PMID: 34763112 DOI: 10.1016/j.ijsu.2021.106176] [Reference Citation Analysis]
129 Schmidt T, Mönig SP. [Therapeutic approach in oligometastatic gastric and esophageal cancer]. Chirurg 2017;88:1024-32. [PMID: 29098307 DOI: 10.1007/s00104-017-0548-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
130 Terashima M, Iwasaki Y, Mizusawa J, Katayama H, Nakamura K, Katai H, Yoshikawa T, Ito Y, Kaji M, Kimura Y, Hirao M, Yamada M, Kurita A, Takagi M, Boku N, Sano T, Sasako M;  Stomach Cancer Study Group;  Japan Clinical Oncology Group. Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). Gastric Cancer. 2019;22:1044-1052. [PMID: 30827001 DOI: 10.1007/s10120-019-00941-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 10.7] [Reference Citation Analysis]
131 Boeken T, Gallois C, Douard R, Méatchi T, Martelli N, Sapoval M, Taieb J, Pellerin O. Bridge to surgery after irinotecan-based liver chemoembolization for metastatic gastric adenocarcinoma: Letter to the editor. Clin Res Hepatol Gastroenterol 2020;:101557. [PMID: 33148485 DOI: 10.1016/j.clinre.2020.08.018] [Reference Citation Analysis]
132 Carmona-bayonas A, Jiménez-fonseca P, Echavarria I, Sánchez Cánovas M, Aguado G, Gallego J, Custodio A, Hernández R, Viudez A, Cano JM, Martínez de Castro E, Macías I, Martín Carnicero A, Garrido M, Mangas M, Álvarez Manceñido F, Visa L, Azkarate A, Ramchandani A, Fernández Montes A, Longo F, Sánchez A, Pimentel P, Limón ML, Arias D, Cacho Lavin D, Sánchez Bayona R, Cerdá P, García Alfonso P. Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry. European Journal of Surgical Oncology 2018;44:1191-8. [DOI: 10.1016/j.ejso.2018.03.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
133 Huang L, Jansen L, Verhoeven RHA, Ruurda JP, Van Eycken L, De Schutter H, Johansson J, Lindblad M, Johannesen TB, Zadnik V, Žagar T, Mägi M, Lagarde SM, Bastiaannet E, van de Velde CJH, Schrotz-King P, Brenner H. Largely varying patterns and trends of primary cancer-directed resection for gastric carcinoma with synchronous distant metastasis in Europe and the US: a population-based study calling for further standardization of care. Ther Adv Med Oncol 2021;13:17588359211027837. [PMID: 34262618 DOI: 10.1177/17588359211027837] [Reference Citation Analysis]
134 Rogers MP, DeSantis AJ, DuCoin CG. Oligometastatic Adenocarcinoma of the Esophagus: Current Understanding, Diagnosis, and Therapeutic Strategies. Cancers (Basel) 2021;13:4352. [PMID: 34503162 DOI: 10.3390/cancers13174352] [Reference Citation Analysis]
135 Tian Y, Zhao Q, Li Y, Fan L, Zhang Z, Zhao X, Tan B, Wang D, Yang P. Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma. Gastroenterol Res Pract 2021;2021:5590626. [PMID: 34335737 DOI: 10.1155/2021/5590626] [Reference Citation Analysis]
136 Mönig S, van Hootegem S, Chevallay M, Wijnhoven BPL. The role of surgery in advanced disease for esophageal and junctional cancer. Best Pract Res Clin Gastroenterol 2018;36-37:91-6. [PMID: 30551863 DOI: 10.1016/j.bpg.2018.11.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
137 Picado O, Dygert L, Macedo FI, Franceschi D, Sleeman D, Livingstone AS, Merchant N, Yakoub D. The Role of Surgical Resection for Stage IV Gastric Cancer With Synchronous Hepatic Metastasis. J Surg Res. 2018;232:422-429. [PMID: 30463751 DOI: 10.1016/j.jss.2018.06.067] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
138 Jamel S, Tukanova K, Markar S. Detection and management of oligometastatic disease in oesophageal cancer and identification of prognostic factors: A systematic review. World J Gastrointest Oncol 2019; 11(9): 741-749 [PMID: 31558978 DOI: 10.4251/wjgo.v11.i9.741] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
139 Liu N, Xu Y, Rahnemai-Azar AA, Abbott DE, Weber SM, Lidor AO. National Underutilization of Neoadjuvant Chemotherapy for Gastric Cancer. J Gastrointest Surg 2020;24:949-58. [PMID: 31792901 DOI: 10.1007/s11605-019-04439-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
140 Dineen SP, Pimiento JM. The Landmark Series: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for Treatment of Gastric Cancer Metastatic to Peritoneum. Ann Surg Oncol 2021;28:4130-7. [PMID: 33856601 DOI: 10.1245/s10434-021-09927-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]